Nong Yang

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · The Lancet Respiratory Medicine · 2022 · 230 citations

Medicine, Oncology, Pharmacology +13

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng, Yun Fan, Yanqiu Zhao et al. · Journal of Thoracic Oncology · 2024 · 132 citations · Full text

Medicine, Oncology, Pharmacology +4

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · Journal of Thoracic Oncology · 2022 · 77 citations

Medicine, Neurology, Pharmacology +6

40Ar/39Ar dating of shear deformation of the Xianshuihe fault zone in west Sichuan and its tectonic significance

Yueqiao Zhang, Wen Chen, Nong Yang · Science in China Series D Earth Sciences · 2004 · 55 citations

Natural Sciences, Earth Sciences, Geology +17